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Concise report
Duration of psoriatic arthritis as a risk factor for
myocardial infarction
Alexander Egeberg1, Lone Skov1, Peter Riis Hansen2, Gunnar H. Gislason2,3,4,
Jashin J. Wu5, Jacob P. Thyssen1 and Lotus Mallbris6
Abstract
Objectives The aim was to examine the association between disease duration and risk of myocar-
dial infarction (MI) in patients with PsA.
Methods We used nationwide registry data from Denmark to estimate incidence rates per 1000
person-years and the risk of MI [adjusted hazard ratios (HRs) with 95% CIs] in rheumatologist-
diagnosed patients with PsA using Cox regression models. The study period was between 1 January
2008 and 31 December 2012.
Results The study population comprised a total of 8071 patients with PsA and 4 348 857 general
population control subjects. A total of 156 and 54 215 MIs occurred during follow-up among patients
with PsA and the reference population, respectively. There was a significant association between the
duration of PsA and risk of MI (adjusted HR ¼ 1.02; 95% CI: 1.01, 1.03 for each additional year after
PsA diagnosis). Stratified based on short (<2 years) and long (2 years) disease duration, the adjusted
HRs were 0.96 (95% CI: 0.60, 1.52; P¼ 0.8487) and 1.29 (95% CI: 1.09, 1.53; P¼ 0.0026), respectively.
Other significant predictors included age, sex, socio-economic status, smoking, alcohol abuse, diabe-
tes, hypertension and previous cardiovascular disease.
Conclusions We observed an increased risk of MI associated with longer duration of PsA. Our
findings call for increased focus on disease duration in the cardiovascular risk assessment among
patients with PsA.
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Introduction
PsA is a chronic inflammatory arthropathy that is fre-
quently associated with skin and/or nail psoriasis. In re-
cent years, cutaneous psoriasis has been associated
with increased risk of cardiovascular disease (CVD), in
particular myocardial infarction (MI) [1]. However, data
on the relationship between PsA and MI are less clear
cut [2, 3]. Chronic systemic inflammation in psoriasis
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. Risk of myocardial infarction remains poorly understood in patients with PsA.
. Duration of PsA was significantly associated with future risk of myocardial infarction.
. Physicians should enquire about disease duration when assessing cardiovascular risk in patients with PsA.
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and PsA may hypothetically increase the risk of MI,
because cumulative exposure to systemic low-grade in-
flammation has been associated with atherosclerotic
CVD [4]. This suggests that a longer duration of inflam-
matory disease, such as PsA, might increase the risk of
CVD, including MI. Therefore, features such as PsA dis-
ease duration, which are easily obtainable by interview
or review of the patient history, might identify those at
higher risk for CVD. Indeed, a small study of angio-
graphic coronary artery disease in psoriasis, and larger
studies in RA and diabetes, have demonstrated that
patients with a longer duration of disease have a higher
risk of CVD, but these studies were limited to either clin-
ical coronary artery disease or non-population-based
methods [5–8]. We therefore examined the effects of
PsA duration on the risk of MI in a nationwide cohort
study in Denmark.
Methods
Data sources and study population
Study approval was obtained from the Danish Data
Protection Agency (ref. 2007-58-0015; int. ref. GEH-
2014-018, I-Suite 02736), and approval from an ethics
committee is not required for registry studies in
Denmark. The study was conducted in accordance with
the Strengthening the Reporting of Observational
Studies in Epidemiology recommendations [9].
The Danish health-care system is tax supported and
provides access to general practitioners, specialists in pri-
vate clinics and public hospitals for all citizens without
charge. A permanent and unique civil registration number
is given to each resident upon birth or migration. This
number allows for unambiguous linkage at an individual
level of a range of administrative registries and clinical
databases [10–13]. This allows for complete and accurate
information on all health-care consultations (e.g. diagno-
ses), pharmacy-dispensed prescriptions, vital statistics and
socio-economic status. Data are encrypted and rendered
anonymous when used for research purposes. Diagnoses
are coded as International Classification of Diseases (ICD)
codes, and pharmacotherapy according to the Anatomical
Therapeutic Chemical classification. Hospital-administered
pharmacotherapy is coded as treatment procedure
[SundhedsvI`senets Klassifikationssystem (SKS)] codes.
The majority of prescriptions in Denmark are claimed at
pharmacies; however, certain drugs, for example, systemic
immunosuppressant agents (including biologics and MTX)
are predominantly given directly from hospital clinics.
The present study comprised all adults (18 years)
alive and resident in Denmark on 1 January 2008 (i.e.
the study start date). All individuals were followed from
the start of the study until 31 December 2012, death,
migration or the occurrence of an end point, whichever
came first. Patients were classified as having PsA if they
had received a diagnosis (inpatient or ambulatory) of
PsA (ICD-10 M07.0-3 or ICD-8 696.09) before the start
of the study.
Pharmacotherapy, co-morbidity and socio-economic
status
We identified baseline pharmacotherapy 6 months be-
fore study inclusion for the following therapies:
adalimumab, cholesterol-lowering drugs, ciclosporin,
etanercept, infliximab, LEF, MTX, SSZ and systemic
CSs. Certolizumab pegol, ustekinumab and golimumab
were not marketed in Europe at the time of study initia-
tion and were thus not included. We assessed baseline
co-morbidity as those of the following conditions that
occurred in the 5-year period before study inclusion:
alcohol abuse, CVD, diabetes and hypertension.
Cardiovascular disease was defined as a composite of
selected medical conditions and revascularization pro-
cedures as previously described [14]. Diabetes was de-
fined by either ICD-code or use of glucose-lowering
drugs. Collection of data on hypertension, smoking and
alcohol abuse has been described elsewhere [15–17].
Socio-economic status was calculated as age-
standardized quintiles of the average 5-year gross an-
nual income at baseline.
Statistical analysis
SAS statistical software version 9.4 (SAS Institute Inc.,
Cary, NC, USA) was used for statistical analysis. The
duration of PsA was calculated as the time difference
between PsA onset and study start. Incidence rates
were summarized per 1000 person-years, and Cox re-
gression analyses were performed to estimate hazard
ratios (HRs). In multivariable models, we adjusted for
age, sex, socio-economic status, cholesterol-lowering
drugs, smoking, alcohol abuse, diabetes, hypertension
and CVD, respectively. We performed separate analy-
ses, in which patients with previous MI were excluded.
Sensitivity analyses were performed, with additional ad-
justment for use of systemic anti-PsA treatment and du-
ration of cutaneous psoriasis, respectively. Patients
were stratified based on whether they had PsA for <2
years (‘short duration’) or 2 years (‘long duration’). This
cut-off has been established previously [18]. Model
assumptions, including the linearity of continuous varia-
bles, absence of interactions and the proportional haz-
ards assumptions, were tested and found to be valid
unless otherwise specified. The proportional hazards
assumptions were tested through significance tests and
graphically assessed using log–log plots. Statistically
significant results were defined as those with P<0.05,
and we report results with 95% CIs were appropriate.
Results
The study population comprised a total of 8071 patients
with PsA and 4 348 857 general population control sub-
jects (Table 1). Among patients with PsA, there was a
slight (56%) female predominance, whereas the reference
population had an equal gender distribution. Patients with
PsA were slightly older (mean age 54.7 vs 48.7 years) at
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baseline and had a mean disease duration of 8 years.
The prevalence of CVD, alcohol abuse, smoking and hy-
pertension, respectively, was higher among patients with
PsA, and a greater proportion of PsA patients had a re-
ceived systemic treatment within the last 6 months before
the start of the study compared with the reference popu-
lation. Among patients with concurrent cutaneous psoria-
sis, the mean (S.D.) disease duration was 9.2 (7.7) and 4.3
(6.6) years for patients with PsA and the reference popu-
lation, respectively.
A total of 156 PsA patients and 54 215 control subjects
experienced a MI during the study period. The incidence
rates per 1000 person-years were 4.06 and 2.61 among
patients with PsA and the reference population, respec-
tively. Stratified by disease duration, the incidence rates
were 2.15 and 4.59 among patients with short duration
and long duration, respectively (supplementary Table S1,
available at Rheumatology Advances in Practice online).
There was a significant association between the duration
of PsA and the risk of MI in crude (HR ¼ 1.05; 95% CI:
1.04, 1.06) and adjusted (HR ¼ 1.02; 95% CI: 1.01, 1.03)
analyses, respectively (Fig. 1). Stratified based on short
and long disease duration, the adjusted HRs were 0.96
(95% CI: 0.60, 1.52; P¼0.8487) and 1.29 (95% CI: 1.09,
1.53; P¼0.0026), respectively. When patients with previ-
ous MI were excluded, that is, in analyses of first-time
MI, the adjusted HR of MI associated with an additional
year of disease duration was 1.02 (95% CI: 1.00, 1.03;
P< 0.05). In analyses stratified based on short and long
disease duration, the adjusted results were 0.99 (95% CI:
0.61, 1.62; P¼0.9737) and 1.29 (95% CI: 1.07, 1.55;
P¼ 0.0085) (Table 2). The results were not significantly al-
tered by adjustment for systemic anti-PsA treatment (ad-
justed HR ¼ 1.02; 95% CI: 1.01, 1.03) or the duration of
cutaneous psoriasis (adjusted HR ¼ 1.02, 95% CI: 1.00,
1.03; P<0.05), respectively. Other significant predictors
of MI included older age, male sex, low socio-economic
status, hypertension, diabetes, smoking, alcohol abuse,
diabetes and previous CVD (supplementary Table S2,
available at Rheumatology Advances in Practice online).
Discussion
In this nationwide study of the Danish population, we
observed a significantly increased risk of MI associated
with the duration of PsA. Our results remained consis-
tent in adjusted models and suggest that disease dura-
tion might be an easily obtainable risk marker when
evaluating cardiovascular risk in patients with PsA, and
possibly also in other inflammatory diseases. Traditional
established MI risk factors, such as age, sex and life-
style factors, were also significantly associated with the
risk of MI, supporting the robustness of our findings.
Data suggest that cutaneous psoriasis lesions mani-
fests on average 10 years before development of PsA
[19]. Consequently, epidemiological studies tend to
identify patients with a shorter duration of PsA
TABLE 1 Baseline characteristics of the study population
Characteristics Reference
population
PsA
population
(n 5 4 348 857) (n 5 8071)
Age, mean (S.D.), years 48.7 (18.0) 54.7 (14.0)
Sex, n (%)
Women 2 208 599 (50.8) 4517 (56.0)
Men 2 140 258 (49.2) 3554 (44.0)
Duration of PsA, mean
(S.D.), years
NA 8.0 (7.0)
Age at disease onset,
mean (S.D.), years
NA 46.7 (13.8)
Socio-economic status, n (%)
Lowest 870 786 (20.0) 743 (9.2)
Below average 869 301 (20.0) 2053 (25.4)
Average 869 276 (20.0) 2071 (25.7)
Above average 869 680 (20.0) 1667 (20.7)
Highest 869 814 (20.0) 1537 (19.0)
Smoking, n (%) 430 808 (9.9) 1316 (16.3)
Co-morbidity, n (%)
Alcohol abuse 60 779 (1.4) 145 (1.8)
Cardiovascular
disease
378 124 (8.7) 1252 (15.5)
Diabetes 157 384 (3.6) 583 (7.2)
Hypertension 526 298 (12.1) 1714 (21.2)
Medicationa, n (%)
Adalimumab 991 (0.0) 199 (2.5)
Cholesterol-lowering
drugs
399 843 (9.2) 1294 (16.0)
Ciclosporin 1126 (0.0) 47 (0.6)
Biologicsb 943 (0.0) 226 (2.8)
Infliximab 1224 (0.0) 108 (1.3)
LEF 123 (0.0) 8 (0.1)
MTX 15 224 (0.4) 2028 (25.1)
SSZ 8874 (0.2) 649 (8.0)
Systemic CSs 88 881 (2.0) 776 (9.6)
aBiologics include etanercept, infliximab, adalimumab, cer-
tolizumab pegol and golimumab. Certolizumab pegol, uste-
kinumab and golimumab were not marketed in Europe at
the time of study start.
bWithin the last 6 months. NA, not applicable.
FIG. 1 Cumulative risk of myocardial infarction
PsA as risk factor for myocardial infarction
www.rheumatology.oxfordjournals.org 3
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
ap/article-abstract/2/1/rky011/4962129 by guest on 11 June 2019
compared with psoriasis. This might explain why the ep-
idemiological data on the risk of CVD is not as consis-
tent for PsA as for RA and psoriasis [2, 3]. Previously,
studies of RA and diabetes have highlighted the impor-
tance of disease duration for the risk of CVD [5–8]. On
the contrary, a small single-centre study found no rela-
tionship between increased duration of psoriasis and in-
creased CVD risk [20], whereas a larger study found a
significantly increased risk of CVD associated with dura-
tion of psoriasis [14].
Contrasting the present findings, one previous study
[21] failed to find an association between disease dura-
tion and the extent of atherosclerosis among patients
with PsA, albeit that only 44% of patients were seen in
the clinic within the first 2 years after the diagnosis.
Certain limitations apply to the interpretation of our
study results, the most important being the observa-
tional nature of our data. Indeed, observational
studies cannot establish a causal relationship, and al-
though our results are biologically plausible and
remained consistent in a number of sub-analyses, the
results should be considered hypothesis generating.
Moreover, it is likely that some patients might not seek
medical treatment in very early and mild stages of
PsA, leading to an underestimation of the disease du-
ration. We did not include adjustment for NSAIDs
because these are also available over the counter in
Denmark. Lastly, we lacked data on obesity/BMI and
on clinical and radiographic findings, and whether dif-
ferences in PsA severity might have affected our
results remains unclear.
In conclusion, we observed an increased risk of MI
associated with a longer duration of PsA. Our findings
call for increased focus on disease duration in CVD risk
assessment among patients with PsA.
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TABLE 2 Risk of myocardial infarction in patients with PsA
Crude HR (95% CI) P-value Adjusteda HR (95% CI) P-value
Risk of myocardial infarction (including patients with previous myocardial infarction)
Duration of PsA, per year 1.05 (1.04, 1.06) <0.0001 1.02 (1.01, 1.03) 0.0038
Duration <2 years 0.82 (0.52, 1.31) 0.4084 0.96 (0.60, 1.52) 0.8487
Duration 2 years 1.76 (1.49, 2.08) <0.0001 1.29 (1.09, 1.53) 0.0026
Risk of first-time myocardial infarction
Duration of PsA, per year 1.05 (1.03, 1.06) <0.0001 1.02 (1.00, 1.03) 0.0131
Duration <2 years 0.88 (0.54, 1.44) 0.6173 0.99 (0.61, 1.62) 0.9737
Duration 2 years 1.71 (1.41, 2.06) <0.0001 1.29 (1.07, 1.55) 0.0085
aAdjusted for age, sex, socio-economic status, cholesterol-lowering drugs, smoking, alcohol abuse, diabetes, hypertension
and previous cardiovascular disease. HR: hazard ratio.
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